Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.74 -0.05 (-0.18%)
Streaming Delayed Price Updated: 11:58 AM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,025,502
Open 28.82
Bid (Size) 28.73 (17)
Ask (Size) 28.74 (18)
Prev. Close 28.79
Today's Range 28.50 - 28.89
52wk Range 28.30 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 5.71%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
These particular players look cheap right now. 
Via The Motley Fool

Performance

YTD
-43.94%
-43.94%
1 Month
-7.83%
-7.83%
3 Month
-16.38%
-16.38%
6 Month
-26.10%
-26.10%
1 Year
-42.19%
-42.19%

More News

Read More
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Via Benzinga
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
Via Benzinga
Topics Stocks
Exposures US Equities
This Is What Whales Are Betting On Pfizer
Via Benzinga
Is Pfizer Stock a Buy Now?
Via The Motley Fool
Why Pfizer Stock Is Sinking Today
Via The Motley Fool
Pfizer Inc. (NYSE: PFE) is One of Friday Morning’s Most Active Stocks
Via Investor Brand Network
Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate
Via Benzinga
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Via MarketBeat
Diamonds in the Rough: 3 Undervalued Stocks with Huge Upside
Via InvestorPlace
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
Via Benzinga
3 Stocks at the Forefront of Personalized Medicine Trend
Via InvestorPlace
7 Compelling Stocks to Buy That are Sitting at 52-Week Lows
Via InvestorPlace
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Via Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
Via MarketBeat
Exposures Product Safety
Pfizer Tumbles After Abandoning Weight-Loss Pill
Via Talk Markets
Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes
Via The Motley Fool
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
5 Top Stocks to Buy Before 2024
Via The Motley Fool
Stocks, Gold, Bonds Rally Further, Dollars Tumbles As Traders Anticipate Fed Cuts: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Is Hub Cyber Security (HUBC) Stock Up 30% Today?
Via InvestorPlace
Why Is Altimmune (ALT) Stock Up 43% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.